-

04:08:17 PM

CYTO Stock News

CYTO - Altamira Therapeutics Ltd

10/03/22 8:47 AM

Nasdaq : CYTO

clinical triallow float

Altamira Therapeutics Continue Bentrio Clinical Trial for Seasonal Allergic Rhinitis in Australia

Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its "NASAR" clinical trial with its Bentrio TM nasal spray for seasonal allergic rhinitis

RHEA-AI

neutral

09/27/22 8:47 AM

Nasdaq : CYTO

low float

Altamira Therapeutics Re-launches Bentrio in Europe for Allergic Rhinitis

Bentrio TM nasal spray becomes available again in selected European countries Marketing focus is on protection against airborne allergens Partnering discussions for distribution in Europe and US expected to conclude in Q4 2022 Altamira

RHEA-AI

neutral

09/13/22 8:47 AM

Nasdaq : CYTO

covid-19low float

Altamira Therapeutics Completes Enrollment for COVAMID Trial with Bentrio in Acute COVID-19

Study has reached extended enrollment target of 160 patients Top-line data read-out expected in Q4-22 Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today

RHEA-AI

neutral

09/08/22 8:57 AM

Nasdaq : CYTO

conferenceslow float

Altamira Therapeutics to Host Investor Call on September 14th

Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced it will hold a call to address questions from investors and discuss the Company's strategy to

RHEA-AI

neutral

09/08/22 7:17 AM

Nasdaq : CYTO

conferenceslow float

Altamira Therapeutics to Participate in the 4th Annual RAS-Targeted Drug Development Summit

Company's Chief Scientific Officer Samuel Wickline, MD, to present on the Company's innovative and patented OligoPhore TM platform for the treatment of KRAS-driven cancers Forum will provide Altamira the opportunity to network with community

RHEA-AI

very positive

08/30/22 9:24 AM

Nasdaq : CYTO

low float

Altamira Therapeutics Provides Business Update

RHEA-AI

neutral

08/03/22 12:15 PM

Nasdaq : CYTO

low float

Altamira Therapeutics' CEO Interviewed by Proactive Investors to Discuss its Pipeline of RNA Therapeutics and Ongoing Strategic Transformation

Altamira's patented RNA delivery technology platform is addressing strong need for reaching target cells outside the liver and for enhanced release of RNA molecules within cells First development projects in oncology and rheumatoid arthritis

RHEA-AI

positive

08/01/22 8:47 AM

Nasdaq : CYTO

covid-19low float

Altamira Therapeutics Completes Interim Sample Size Analysis of COVAMID Trial with Bentrio in Acute COVID-19

Enrollment to be continued to 160 subjects, adding 24 to ensure adequate statistical power Top-line data read-out from trial expected in early Q4-22 COVAMID trial essential for potential label expansion into viral infection in important

RHEA-AI

neutral

07/28/22 8:47 AM

Nasdaq : CYTO

low float

Altamira Therapeutics' Delivery Platform with siRNA Shown to be Effective Treatment for Osteoarthritis as Published in Peer-Reviewed Journal

RHEA-AI

negative

07/25/22 8:47 AM

Nasdaq : CYTO

low float

Altamira Therapeutics to Develop Novel Generation of Rheumatoid Arthritis Therapeutics Based on its Proprietary OligoPhore Delivery Platform and siRNA Targeting Key Inflammation Checkpoint

oCompany's novel drug development program AM-411 builds on positive animal data oTreatments for rheumatoid arthritis represent the second largest therapeutic area globally oAM-411 to run concurrently with AM-401 (KRAS-driven cancers) to leverage platform data Hamilton, Bermuda, July 25, 2022

RHEA-AI

neutral

1 2 3 4 5 6 Next

CYTO Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.aurismedical.com
CeoThomas Meyer
Security nameAltamira Therapeutics Ltd
Issue typecs
SectorManufacturing
Sic code2834
Employees9
AddressBahnhofstrasse 21
StateZug
CityZug
Zip6300
CountrySwitzerland
Phone41417297194

About Altamira Therapeutics Ltd

Altamira Therapeutics is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in three areas: the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore™ / SemaPhore™ platforms; preclinical), nasal sprays for protection against airborne viruses and allergens (Bentrio™; commercial) or the treatment of vertigo (AM-125; Phase 2), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®, Phase 3). The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Altamira Therapeutics Ltd. trade on the NASDAQ Capital Market under the symbol "CYTO."